Is Allergan Worth Over $300 Without Pfizer?

Allergan plc Ordinary Shares (NYSE: AGN) plummeted this week as news broke that Pfizer Inc. (NYSE: PFE) and Allergan will be terminating their proposed merger. The stock may have taken a hit, but a pair of Wall Street analysts believe that there’s plenty of value in a stand-alone Allergan.

Deutsche Bank’s Gregg Gilbert recently set a standalone target price of $282 for Allergan, even though the company now faces a pair of short-term headwinds associated with the terminated deal. First, Allergan’ employees have likely been understandably distracted and concerned about the potential deal, and the company’s workforce production has likely suffered.

Related Link: Allergan Now Trades Cheaper Than Its Standalone Value

“With investor sentiment at poor levels for the space, and the natural skepticism that may follow when a company had agreed to sell itself, some investors may take a more wait-and-see approach,” Gilbert adds.

Deutsche Bank maintains a Buy rating on Allergan.

Citi analyst Liav Abraham believes Allergan will now go right back to prior focus on fundamentals.

“Over the near term, we expect the cost cutting recently excluded from estimates pending the closure of the PFE/AGN transaction to be re-implemented,” Abraham notes.

Citi is even more bullish on the standalone stock that Deutsche Bank and maintains a Buy rating and $360 price target.

Disclosure: the author holds no position in the stocks mentioned.